Life science equity crowdfunding platform CAPITAL CELL shortlisted for international award

Life science equity crowdfunding platform CAPITAL CELL

Life science equity crowdfunding platform CAPITAL CELL shortlisted for international award

Today, Capital Cell, Europe’s first equity crowdfunding platform specialised in life science,
has been shortlisted for the prestigious Best International Growth Business award at the UK Business Angels Association Investment Awards 2017.

Capital Cell has been trading in Spain for just over 2 years, and has successfully closed 14 life science crowdfunding campaigns, including the country’s largest life science crowdfunding campaign of over €1.2M, for a potential therapeutic cure for MS.
Scaling-up from this Spanish platform, Capital Cell UK has just launched at
www.capitalcell.co.uk, with a range of companies solving unmet needs from malaria control to female fertility enhancement and autoimmune disease.

In recognition of their contribution to the European life science ecosystem, the company has now been shortlisted for the Best International Growth Business award at the UK Business Angels Association Investment Awards 2017. ‘We are absolutely thrilled that Capital Cell has been recognised so early on in it’s expansion into the UK,’ says Laura Ferguson, UK Director. ‘The reception to our arrival has been overwhelmingly positive from players throughout the life science ecosystem, including specialised investors such as Angels in MedCity, with whom we are collaborating closely, as well as the NHS innovation, science parks and startup incubators. It’s wonderful to have that traction formally recognised’.

Life science equity crowdfunding platform Capital Cell has already proven itself as a platform for early stage investment in a very challenging environment’, Chairman Ian Tomlinson adds, ‘so we are extremely excited about scaling up in the UK, which is a global leader not only in life science innovation but also in equity crowdfunding. As an investment area, life science has the potential for both huge social impact and significant financial returns and the companies listed on Capital Cell are all trying to solve a major unmet medical need. By opening up these investment opportunities to more people we hope to be able to help the UK remain at the cutting edge of life science commercialisation.’
The UKBAA black-tie awards dinner will take place on July the 6th, at the Dorchester Hotel,
London, with 300 leading innovators and investors assembled to celebrate the best of UK
business.
Capital Cell Ltd (FRN 774677) is an Appointed Representative of Larpent Newton & Co Ltd. Larpent Newton & Co Ltd is authorised and regulated by the Financial Conduct Authority, FRN 141275. Life science equity crowdfunding platform.

Life science equity crowdfunding platform CAPITAL CELL shortlisted for international award

Life science equity crowdfunding platform CAPITAL CELL shortlisted for international award

Life science equity crowdfunding platform CAPITAL CELL shortlisted for international award

Life science equity crowdfunding platform – CAPITAL CELL – Life science equity crowd funding platform – Life science equity crowdfunding platform